Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?

The widespread use of drugs that bind diffusible vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular age-related macular degeneration (AMD). The pivotal ranibizumab and aflibercept registration trials featured monthly intravitreal injections for 12 months, durin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Michael W. Stewart
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2015-05-01
Colecção:Journal of Clinical Medicine
Assuntos:
age-related macular degeneration
as-needed therapy
bevacizumab
choroidal neovascularization
monthly therapy
ranibizumab
treat and extend
Acesso em linha:http://www.mdpi.com/2077-0383/4/5/1079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados